Amivantamab联合拉泽替尼及贝伐珠单抗治疗EGFR突变晚期NSCLC获性耐药
ETOP 18-21 AMAZE-lung是一项前瞻性、国际、多中心、单臂2期试验,评估amivantamab、拉泽替尼和贝伐珠单抗联合方案用于第三代EGFR TKI获得性耐药的EGFR突变晚期非鳞NSCLC。安全性可控,最常见治疗相关不良事件为输液反应和痤疮样皮疹。
要点
- 联合方案在第三代EGFR TKI耐药后显示持久抗肿瘤活性,12周ORR达33%。
- 最常见治疗相关不良事件为输液反应(58%)和痤疮样皮疹(50%)。
- 3-4级治疗相关不良事件发生率为43%,未观察到治疗相关死亡。
核心结论
- Amivantamab联合拉泽替尼及贝伐珠单抗在第三代EGFR TKI耐药后显示持久抗肿瘤活性,为有前景的去化疗选择。
- 安全性特征与已知毒性谱一致。
研究设计与样本
- ETOP 18-21 AMAZE-lung为前瞻性、国际、多中心、单臂2期试验,纳入61例患者,主要分析基于前60例意向治疗人群。
- 纳入成人晚期非鳞NSCLC伴EGFR敏感突变(19外显子缺失或21外显子L858R),第三代EGFR TKI(奥希替尼或拉泽替尼)一线或二线治疗后进展。
- 治疗方案:amivantamab静脉固定剂量1400 mg或1750 mg(体重≥80 kg)每3周,2周期后改为1750 mg或2100 mg(体重≥80 kg)每3周;拉泽替尼口服240 mg每日;贝伐珠单抗15 mg/kg每3周。
主要发现
- 总体61例中24例(39% [95%CI 27-53])达部分缓解(22例后续确认)。
- 任何级别治疗相关不良事件最常见为输液反应(35/60,58%)和痤疮样皮疹(30/60,50%)。
- 治疗相关静脉血栓栓塞任何级别10例(17%),3-4级2例(3%);3-4级TRAE 26例(43%),严重TRAE 12例(20%);未观察到治疗相关死亡。
关键数值与推荐
- 总体ORR 39%(95%CI 27-53),部分缓解24/61例。
- 3-4级TRAE发生率43%(26/60),严重TRAE 20%(12/60)。
- 治疗相关静脉血栓栓塞任何级别17%(10/60),3-4级3%(2/60)。
临床怎么用
- 对于第三代EGFR TKI进展后的EGFR突变晚期NSCLC,amivantamab联合拉泽替尼及贝伐珠单抗可作为去化疗的选择。
- 治疗期间需监测输液反应、痤疮样皮疹及静脉血栓栓塞等不良事件。
局限性
- 单臂2期试验,无对照组,样本量有限(61例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MET and angiogenic pathways are activated in EGFR-mutant non-small-cell lung cancer (NSCLC) upon resistance to tyrosine-kinase inhibitors (TKIs). Amivantamab, an EGFR and MET bispecific antibody, is approved in combination with chemotherapy for EGFR-mutant NSCLC post-osimertinib progression based on results of the MARIPOSA-2 trial. We assessed the activity and safety of combined amivantanab, lazertinib, and bevacizumab-a chemotherapy-sparing strategy-for patients with EGFR-mutant NSCLC and acquired resistance to a third-generation EGFR TKI. METHODS: ETOP 18-21 AMAZE-lung was a prospective, international, multicentre, single-arm, phase 2 trial. Adults (aged ≥18 years) with advanced stage, pathologically confirmed non-squamous NSCLC harbouring a sensitising EGFR mutation (exon 19 deletion or exon 21 L858R, or both) with disease progression following treatment with a third-generation EGFR TKI (osimertinib or lazertinib) given in the first-line or second-line setting were included. Patients received intravenous amivantamab at a fixed dose of 1400 mg or 1750 mg (if bodyweight ≥80 kg) every 3 weeks for two cycles, then 1750 mg or 2100 mg (if bodyweight ≥80 kg) every 3 weeks from cycle three; oral lazertinib at a daily dose of 240 mg; and bevacizumab at a dose of 15 mg per kg every 3 weeks. Treatment was given until progression or intolerable toxicity. The primary outcome was 12-week objective response rate (defined by Response Evaluation Criteria in Solid Tumours version 1.1), evaluated in the first 60 patients enrolled (intention-to-treat population). To reject an objective response rate of 20% or less versus 40%, at least 19 responses needed to be observed (2·2% significance level with 93% power). Safety was evaluated in terms of any-cause adverse events and treatment-related adverse events (TRAEs) graded according to Common Terminology Criteria for Adverse Events version 5.0, assessed in all enrolled patients who received at least one dose of trial treatment. The trial is registered on ClinicalTrials.gov (NCT05601973) and in the European Medicines Agency's Clinical Trials Information System (EU CT number 2021-002337-42); the primary analysis is complete but follow-up for patients on treatment is ongoing. FINDINGS: Between March 27, 2023, and May 21, 2024, 61 patients were enrolled from 17 sites in Europe. Median age was 65 years (IQR 61-70), and most patients were female (43 [70%]) and White (50 [82%]). 37 (61%) patients had never smoked, 38 (62%) had Eastern Cooperative Oncology Group performance status 1, and 37 (61%) had stage IVB cancer. All tumours were of adenocarcinoma histology and 18 (30%) patients had asymptomatic brain metastases at screening. At the time of the primary analysis (database cutoff Aug 26, 2024), median follow-up was 9·0 months (IQR 5·8-12·6) and 28 patients were still receiving the treatment combination. Objective response by 12 weeks was shown for 20 patients among the first 60 enrolled (objective response rate 33% [95·6% CI 21-47]), successfully rejecting an objective response rate of 20% or less. Overall, 24 of 61 (39% [95% CI 27-53]) patients showed partial response (22 confirmed at subsequent tumour evaluation). The most commonly reported TRAEs of any grade were infusion-related reaction (35 [58%] of 60 patients) and acneiform rash (30 [50%] of 60 patients). Treatment-related venous thromboembolism of any grade and grade 3-4 was reported in ten (17%) and two (3%) patients, respectively. No treatment-related deaths were observed. Grade 3-4 TRAEs occurred in 26 (43%) of 60 patients, with serious TRAEs observed in 12 (20%) of 60 patients. INTERPRETATION: Combined amivantamab, lazertinib, and bevacizumab showed durable anti-tumour activity, representing a promising chemotherapy-sparing alternative after progression on third-generation EGFR TKIs. Safety was consistent with known toxicity profiles. FUNDING: The ETOP IBCSG Partners Foundation and Janssen Pharmaceutica.
引用
- Soo RA, Popat S, Dafni U, et al. Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2026. PMID: 42833236. doi:10.1016/S2213-2600(26)00203-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。